Compare Smith & Nephew plc (SNN) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Health Care Select Sector SPDR Fund — how do they compare? Smith & Nephew plc trades at $27.67 (market cap $11.63B), while Health Care Select Sector SPDR Fund trades at $167.29. The key difference: Smith & Nephew plc pays a 2.85% dividend while Health Care Select Sector SPDR Fund pays none, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SNN | XLV | |
|---|---|---|
Market Cap | $11.63B | — |
Sector | Health | — |
52-Week High | $38.53 | $175.68 |
52-Week Low | $27.80 | $134.13 |
Enterprise Value | $14.66B | — |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
XLV trades at $167.16, down 2.5% amid testing key support levels, with technical indicators showing mixed signals between bullish moving averages and bearish oscillators. The healthcare ETF maintains defensive appeal with upcoming dividend payments and steady institutional interest, though recent options activity shows increased put volume. Healthcare sector momentum remains supported by strong earnings and defensive positioning in volatile markets.
Outlook remains cautiously optimistic given healthcare's defensive characteristics and potential Fed rate hike benefits, though near-term technical weakness and sector-specific headwinds like drug trial failures present risks. The ETF's low expense ratio and diversification across 60 healthcare stocks provide stability for long-term investors seeking sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
